Oryzon Genomics (BME: ORY)

Last close As at 21/12/2024

EUR1.55

−0.05 (−2.89%)

Market capitalisation

EUR102m

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Latest Insights

View More

Healthcare | edison tv

Oryzon Genomics – executive interview

Healthcare | Flash note

Oryzon Genomics — FDA aligns on Phase III BPD plans

testalize-me-0jE8ynV4mis-unsplash

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Carlos Buesa

    CEO

Further insights

insight

Epigenetics

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free